Prostate 2010,70(8):817–824.see more PubMedCrossRef 14. Papadimitraki ED, Tzardi M, Bertsias G, Sotsiou E, Boumpas DT: Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus 2009,18(9):831–835.PubMedCrossRef 15. Summers SA, Steinmetz OM, Ooi JD, Gan PY, O’Sullivan KM, Visvanathan K, Akira S, Kitching AR, Holdsworth SR: Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Am J Pathol 2010,177(5):2234–2244.PubMedCrossRef 16. Summers SA, Hoi A, Steinmetz OM, Tanespimycin ic50 O’Sullivan KM, Ooi JD, Odobasic D,
Akira S, Kitching AR, Holdsworth SR: TLR9 and TLR4 are required for the development of STI571 supplier autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun 2010,35(4):291–298.PubMedCrossRef 17. Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM: Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009,7(3):E58–65.PubMedCrossRef 18. Ronkainen H, Vaarala MH, Kauppila S, Soini Y, Paavonen TK, Rask J, Hirvikoski P: Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage
and poor differentiation in renal cell carcinoma. Oncol Rep 2009,21(6):1519–1523.PubMed 19. Ronkainen H, Hirvikoski P, Kauppila S, Vaarala MH: Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma. Oncol Rep 2011,25(1):129–133.PubMed 20. UICC: TNM Classification of Malignant Tumours. 6. Wiley & Sons, New York; 2002. 21. IARC: Tumours OSBPL9 of the Urinary System and Male Genital Organs. IARC Press, Lyon; 2004. 22. Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, Selander KS: Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate
Immun 2008,1(1):59–68.PubMedCrossRef 23. Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, Gonzalez-Quintana JM, Vizoso FJ: Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010, 10:665.PubMedCrossRef 24. Tanaka J, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K, Kojima T, Takei Y: Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 2010,37(4):805–814.PubMedCrossRef 25. Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M: Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 2010,70(23):9816–9826.PubMedCrossRef 26.
No related posts.